Clinical Trial Update: Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating nintedanib for SARS-CoV-2-induced pulmonary fibrosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Fibrosis

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: SARS-Cov-2 Induced Pulmonary Fibrosis | Phase 3 | Status: RECRUITING